Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Jan 29 · inside the Ichimoku cloud · RSI 17 (oversold) · MACD above its signal · at its 52-week low
| 0.001000 | 52-week high | +900.00% |
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month high | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week low | −0.00% |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | 900.0 | 0.0 | 900.0 | -90.0 | −0.0% |
| 2024 | -43.8 | -20.9 | 22.1 | -99.8 | 0.0 | 1100.0 | 0.0 | 0.0 | 0.0 | 0.0 | -99.2 | 0.0 | −100.0% |
| 2023 | 70.7 | -21.9 | -26.3 | 10.6 | -18.7 | 29.9 | 1.5 | -21.5 | -19.4 | -1.8 | -42.1 | -37.4 | −73.8% |
| 2022 | -9.1 | 12.2 | -14.1 | -46.2 | -1.2 | -1.7 | 10.6 | -34.6 | -53.2 | -52.2 | -52.6 | 24.0 | −95.7% |
| 2021 | -31.7 | -19.6 | −45.1% |
No insider transactions reported for UTRS.
None of the 29 investors followed here reported a position in UTRS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a UTRS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps; and HERizon electronic disposable hysteroscope, image processor, Hysto-Kit, and endoscopic accessories that helps gynecologists to evaluate abnormal uterine bleeding and provide care. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
No recent headlines.